WuXi Biologics (Cayman) Inc. (WuXi Biologics (Cayman) Inc.) issued a Clarification Notice on March 7, 2024, in response to a procedural hearing held by the U.S. Senate on March 6 on the draft amendment bill. The company clarified that it is not a subsidiary of Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd., and operates independently. As a global biopharmaceutical CRDMO platform, the company does not engage in human genomics business, nor does it collect human genome data, nor does it pose a risk to national security in the United States or other countries. THE COMPANY WILL CONTINUE TO FOCUS ON THE LEGISLATIVE PROCESS OF THE DRAFT AMENDMENT BILL AND URGES SHAREHOLDERS AND POTENTIAL INVESTORS TO EXERCISE CAUTION WHEN TRADING THE COMPANY'S SECURITIES.

WuXi Biologics (Cayman) Inc. (WuXi Biologics (Cayman) Inc.) issued a Clarification Notice on March 7, 2024, in response to a procedural hearing held by the U.S. Senate on March 6 on the draft amendment bill. The company clarified that it is not a subsidiary of Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd., and operates independently. As a global biopharmaceutical CRDMO platform, the company does not engage in human genomics business, nor does it collect human genome data, nor does it pose a risk to national security in the United States or other countries. THE COMPANY WILL CONTINUE TO FOCUS ON THE LEGISLATIVE PROCESS OF THE DRAFT AMENDMENT BILL AND URGES SHAREHOLDERS AND POTENTIAL INVESTORS TO EXERCISE CAUTION WHEN TRADING THE COMPANY'S SECURITIES.